HCPCS Code J0600: Injection, edetate calcium disodium, up to 1000 mg

Key takeaways

HCPCS Code J0600 covers injection of edetate calcium disodium, up to 1,000 mg, sold as Calcium Disodium Versenate.

Medicare Part B pays J0600 under the buy-and-bill model, at ASP plus 6%, with rates updated quarterly.

Modifier JA marks intravenous administration. Modifier JB means subcutaneous, so it does not fit an intramuscular dose.

ICD-10 linkage from the T56.0X series, unit counts per 1,000 mg, and NDC reporting on Medicaid claims are the top denial points.

Pabau pulls the dose, route, and diagnosis already on the patient record into a pre-filled claim for submission.

HCPCS Code J0600 is a Level II code covering injection of edetate calcium disodium, up to 1,000 mg. It bills the chelating agent used to treat lead poisoning, sold under the brand name Calcium Disodium Versenate.

Most J0600 denials trace back to three problems. A missing or mismatched ICD-10 code, an incorrect unit count, or an absent NDC on a Medicaid claim. None of them are clinical. This reference covers the drug, the Part B payment structure, and the documentation each payer expects.

HCPCS Code J0600: definition and quick reference

HCPCS Code J0600 is a Level II HCPCS code maintained by the Centers for Medicare and Medicaid Services (CMS). It describes a single billable unit of edetate calcium disodium injection, up to 1,000 mg, administered by intravenous (IV) or intramuscular (IM) route. The short descriptor used by payers and clearinghouses is “Edetate calcium disodium inj.”

J-codes sit within HCPCS Level II and cover drugs administered by methods other than oral. J0600 falls in the J0100-J8999 drug administration range. The code has remained active without modification since its original inclusion in the HCPCS code set, and the 2026 version is effective January 1, 2026.

Clinical overview: what drug does J0600 cover?

Edetate calcium disodium (CaEDTA) is a chelating agent. It binds to lead ions in the bloodstream and moves them out through the urine. That makes it the primary drug treatment for lead poisoning and lead encephalopathy. The brand name is Calcium Disodium Versenate.

FDA approval covers two indications: acute lead poisoning (blood lead levels warranting treatment) and lead encephalopathy. Off-label use outside these indications is not supported by the FDA label and requires additional documentation to establish medical necessity for payer purposes. Clinicians billing J0600 for anything outside the approved indication should consult their compliance officer before submission.

The route of administration drives what the claim has to say. Modifier JA identifies intravenous administration, and Medicare requires it on IV claims for J0600. Modifier JB means subcutaneous administration, so no JA-family modifier covers an intramuscular dose. Document the route in the note either way.

• Generic name: Edetate calcium disodium
• Chemical abbreviation: CaEDTA
• Brand name: Calcium Disodium Versenate
• Mechanism: Chelating agent that binds lead and promotes renal excretion
• FDA-approved indications: Acute lead poisoning, lead encephalopathy
• Routes: Intravenous (preferred for severe cases), intramuscular
• Billing relevance: Modifier JA applies to the intravenous route

Every encounter note should record the blood lead level, the clinical indication, and the route of administration. Add the dose given and the ordering provider’s name. That record directly supports the medical necessity documentation payers require for J0600. A medication log template holds the same fields whether the drug is a vitamin blend or a chelating agent.

J0600 Medicare reimbursement and fee schedule

Medicare Part B reimburses J0600 under the Average Sales Price (ASP) + 6% methodology. CMS updates ASP-based drug payment rates quarterly. Any dollar figure printed in a reference guide may already be out of date by the time a biller reads it. Always verify the current rate directly from the CMS ASP pricing files before submitting claims.

The ASP + 6% formula means the reimbursement includes the drug’s acquisition cost (ASP) plus a 6% add-on to cover handling and administration overhead. This is the standard Part B drug reimbursement model for physician-administered drugs billed under J-codes.

Under the buy-and-bill model, the practice purchases edetate calcium disodium from a wholesaler or pharmacy. It then administers the drug and bills Medicare Part B using J0600. The practice’s acquisition cost compared to the ASP-based reimbursement determines the margin. Practices relying on this model for IV therapy and injectable drug administration should track acquisition costs against reimbursement rates each quarter.

J0600 coverage: Medicare, Medicaid, and commercial payers

Medicare Part B covers J0600 when medical necessity is established. No national coverage determination applies to edetate calcium disodium. Local coverage determinations from your Medicare Administrative Contractor may still apply, depending on the jurisdiction you bill in. Check your MAC’s published billing articles before the first submission.

Most state Medicaid plans cover edetate calcium disodium for lead poisoning. Coverage rules and prior authorization requirements still differ from state to state. Medicaid also requires NDC reporting on drug claims (see the NDC crosswalk section below). Commercial payers generally follow Medicare coverage criteria, but prior authorization is common. Verify each payer’s drug policy before administration to avoid a post-service denial.

ICD-10 codes used with J0600

Every J0600 claim must include a supporting ICD-10-CM diagnosis code that establishes medical necessity. The primary codes map to the T56.0X series for lead poisoning and the Z77.011 code for contact with and exposure to lead. Using a code outside this set without clinical justification is a denial risk.

The 7th character matters. “A” indicates the initial encounter (acute treatment phase), “D” indicates a subsequent encounter (follow-up or ongoing treatment), and “S” indicates sequela. Most active chelation therapy visits code to “A” or “D” depending on where in the treatment course the visit falls. Using the wrong 7th character is a common coding error that triggers edits without always generating an outright denial, leading to underpayment that goes unnoticed. Practices managing HIPAA-compliant medical office records should include 7th character documentation in their coding audit checklist.

J0600 billing guidelines and documentation requirements

Accurate billing for HCPCS Code J0600 rests on units, modifiers, place of service codes, and supporting documentation. Payer claim-editing systems validate each element on its own. One missing field can trigger a denial even when the clinical record is complete.

Billing units: how to bill per 1,000 mg

One unit of J0600 equals up to 1,000 mg of edetate calcium disodium. If 2,000 mg is administered in a single session, bill 2 units. If 500 mg is administered, bill 1 unit (the “up to” language covers doses at or below 1,000 mg per unit).

Modifiers applicable to J0600

Modifier JA is the route modifier that applies to J0600, and Medicare expects it on every intravenous claim. Modifier JB describes subcutaneous administration, so it has no place on a J0600 claim. There is no JA-family modifier for the intramuscular route. Other modifiers apply in narrower scenarios.

Place of service codes for J0600

Place of service (POS) codes affect the payment rate. J0600 administered in a physician office (POS 11) triggers the non-facility rate. Hospital outpatient (POS 22), off-campus outpatient hospital (POS 19), and inpatient hospital (POS 21) settings trigger the lower facility rate. For hospital facility billing, revenue code 636 (drugs requiring specific identification) typically accompanies J0600.

Practices running IV therapy services mostly administer chelation therapy in the office. Confirm that the registered place of service matches the POS code on the claim. A mismatch between the physical location and the claimed POS code is an audit flag.

NDC crosswalk for J0600

National Drug Code (NDC) reporting is required for all Medicaid drug claims and is increasingly required by commercial payers as well. Each NDC maps to a specific manufacturer’s product. The NDC must match the actual product administered, not a generic equivalent from a different manufacturer.

Edetate calcium disodium is manufactured by a limited number of companies. The table below shows representative NDC formats. Always check the NDC on the product vial label before billing. NDC numbers are product-specific and change when a manufacturer updates packaging. CMS publishes updated NDC crosswalk files quarterly.

Submitting an incorrect or outdated NDC on a Medicaid claim triggers a rejection at the claims processing level before any clinical review occurs. This is one of the cleanest denial-prevention opportunities for practices billing J0600 regularly. For staff managing IV therapy intake and documentation workflows, building the NDC verification step into the pre-billing checklist is the most reliable fix.

Related and crosswalk HCPCS codes

Several HCPCS codes sit close to J0600 in the injectable drug range, including J1364 and J0153. Knowing the neighbors prevents mis-coding and helps billers answer payer crosswalk requests.

For intravenous administration, bill J0600 alongside the infusion administration code. That is CPT 96365 for the first hour, plus 96366 for each additional hour. The drug code and the administration code are separate line items. Billing only J0600 without the infusion administration code, or only the administration code without J0600, both result in incomplete claims. For practices building billing workflows into their practice management system, pairing the drug and administration codes can be automated as a code-set rule.

Common billing errors and claim denials for J0600

Few reference pages catalog the denial patterns for HCPCS Code J0600. The five errors below account for most J0600 rejections in physician office and outpatient settings.

• Missing ICD-10 linkage: Submitting J0600 without a supporting T56.0X series code or Z77.011 is the single most common denial trigger. The claim processor cannot establish medical necessity without a diagnosis code that directly supports chelation therapy.
• Incorrect unit calculation: Billers sometimes report 1 unit regardless of the actual dose. A 2,000 mg infusion billed as 1 unit produces a 50% underpayment, and payers will not catch it on your behalf.
• Missing route modifier: Medicare requires JA on intravenous J0600 claims. Without it, the claim fails front-end edits before clinical review begins. Modifier JB is the subcutaneous modifier and does not substitute for it.
• Absent NDC on Medicaid claims: Medicaid managed care organizations and fee-for-service programs require NDC reporting. A claim without the NDC number, qualifier (N4), or unit of measure is returned unprocessed.
• Wrong place of service code: POS 11 claims the office rate. Use it for a service delivered in a hospital outpatient setting and the claimed rate sits above what the payer will pay. Expect a downward adjustment, or a denial pending documentation.

All five are structured data problems rather than clinical judgment calls. That makes them fixable upstream, at the point where the dose, route, diagnosis, and NDC are recorded. Whoever builds the claim then works from a complete record instead of chasing the missing field.

How to streamline J0600 billing with practice management software

Chelation therapy claims are low-volume for most practices, yet the documentation rules are specific enough to produce the same errors month after month. Each of the five denial types above starts where information is copied by hand from the clinical note onto the claim form.

Practice management software like Pabau keeps that information in one structured record instead of on paper. Digital intake forms and treatment notes capture the fields payers audit on a J0600 claim: blood lead level, dose in mg, route, and clinical indication. Your coder reads the record rather than reconstructing the visit.

From there, claims management pulls the codes and details already on the record into a pre-filled claim. It submits and tracks that claim through Claim.MD for US payers. Pabau does not choose the HCPCS code or adjudicate the claim for you. Your biller still owns the coding decision, with the supporting detail already in front of them.

That matters most for practices running injectable protocols, whether that is an IV therapy EMR or a functional medicine practice. The compliance tools keep an audit trail your MAC can follow if a J0600 claim is reviewed.

Keep J0600 documentation and claims in one record

Pabau captures dose, route, and diagnosis in the patient record, then pulls those details into a pre-filled claim you can submit and track. Your biller keeps the coding decision, with the evidence already attached.

Book a demo

Conclusion

J0600 is a forgiving code to bill once the record is right. The indications are narrow, the unit structure is simple, and the modifier and NDC rules hold steady across payers. Rework comes from the handoff: an undocumented route, a miscounted unit, or an NDC recalled from memory instead of read off the vial.

Fix that handoff and the denial rate follows. Capture the route and dose at the point of care, check the NDC against the label, and count units against the 1,000 mg increment. Book a demo to see how Pabau keeps that detail attached to the claim.

Continue your research

Comparing claims tools before you switch? Pabau vs Waystar sets out what each platform does with the data already on the patient record.

Billing the infusion alongside the drug? 96365 explains how the administration line is timed and documented.

Auditing your medication records? Medication review template gives you a structured format for checking doses and indications.

Opening a service that administers injectables? How to open an IV therapy clinic covers the regulatory and documentation setup.

Frequently asked questions